Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2006 1
2007 1
2008 1
2010 1
2012 1
2013 1
2016 1
2017 1
2018 4
2019 3
2020 2
2021 3
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Among authors: cresta s. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
Anthracyclines.
Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G. Gianni L, et al. Among authors: cresta s. Cancer Chemother Biol Response Modif. 2002;20:59-69. Cancer Chemother Biol Response Modif. 2002. PMID: 12703200 Review. No abstract available.
Anthracyclines.
Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G. Gianni L, et al. Among authors: cresta s. Cancer Chemother Biol Response Modif. 2003;21:29-40. Cancer Chemother Biol Response Modif. 2003. PMID: 15338739 Review. No abstract available.
Cardiotoxic effects of anthracycline-taxane combinations.
Perotti A, Cresta S, Grasselli G, Capri G, Minotti G, Gianni L. Perotti A, et al. Among authors: cresta s. Expert Opin Drug Saf. 2003 Jan;2(1):59-71. doi: 10.1517/14740338.2.1.59. Expert Opin Drug Saf. 2003. PMID: 12904125 Review.
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.
Rivoltini L, Camisaschi C, Fucà G, Paolini B, Vergani B, Beretta V, Damian S, Duca M, Cresta S, Magni M, Leone BE, Castelli C, de Braud F, De Santis F, Di Nicola M. Rivoltini L, et al. Among authors: cresta s. Sci Rep. 2024 Feb 9;14(1):3379. doi: 10.1038/s41598-024-54041-9. Sci Rep. 2024. PMID: 38336861 Free PMC article. Clinical Trial.
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Lorusso D, Maltese G, Sabatucci I, Cresta S, Matteo C, Ceruti T, D'Incalci M, Zucchetti M, Raspagliesi F, Sonetto C, Sinno V, Ronzulli D, Giolitto S, de Braud F. Lorusso D, et al. Among authors: cresta s. Target Oncol. 2021 Jan;16(1):59-68. doi: 10.1007/s11523-020-00780-4. Epub 2020 Dec 28. Target Oncol. 2021. PMID: 33369704 Free PMC article. Clinical Trial.
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
Jhaveri K, Juric D, Yap YS, Cresta S, Layman RM, Duhoux FP, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. Jhaveri K, et al. Among authors: cresta s. Clin Cancer Res. 2021 Nov 1;27(21):5760-5770. doi: 10.1158/1078-0432.CCR-21-1095. Epub 2021 Aug 25. Clin Cancer Res. 2021. PMID: 34433648 Free PMC article.
21 results